Personalized blood-thinning treatment after heart procedures
Precision antiplatelet therapy after percutaneous coronary intervention
This study is looking at how to customize blood-thinning medications for people who have had heart procedures, by checking a specific gene that influences how well these medications work, so that each patient can get the best treatment to lower their risk of heart problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-10875366 on NIH RePORTER |
What this research studies
This research investigates how to tailor blood-thinning medications for patients who have undergone a procedure to open blocked arteries in the heart. It focuses on the role of a specific gene, CYP2C19, which affects how well certain medications work for different individuals. By analyzing patients' genetic information, the study aims to determine the best medication strategy to reduce the risk of heart-related complications. This personalized approach could lead to more effective treatment plans based on each patient's genetic makeup.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who have undergone percutaneous coronary intervention and may carry the CYP2C19 loss-of-function allele.
Not a fit: Patients who have not undergone percutaneous coronary intervention or do not have any genetic variations affecting medication metabolism may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the effectiveness of blood-thinning treatments, reducing the risk of heart attacks and strokes for patients.
How similar studies have performed: Previous research has shown promising results in using genetic information to guide medication choices, indicating that this approach could be effective.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Cavallari, Larisa Humma — University of Florida
- Study coordinator: Cavallari, Larisa Humma
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.